BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors

Current Opinion in Investigational Drugs

Volumn 9, Issue 12, 2008, Pages 1336-1346

  Minkovsky, N ^a   Berezov, A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIBF 1120; BIBW 2992; CANERTINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL TUMOR; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; FOLLICULITIS; GLIOMA; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATENT; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, INVESTIGATIONAL; HUMANS; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 57349141390     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. 303414 Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Science 1987 235 4785 177-182
2. 455043 Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ Cancer 1996 78 6 1284-1292
3. 489663 Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI Cell 1989 58 2 287-292
4. 518465 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S et al Chin J Clin Oncol 2002 20 3 719-726
5. 635092 BIBW-2992, an irreversible dual EGFR/HER-2 receptor tyrosine kinase inhibitor for cancer therapy. BlechSolca F, Baum A, Guth B, Colbatzky F, Blech S, Amelsberg A, Himmelsbach F Clin Cancer Res 2005 11 23 Suppl Abs A 244
6. 635097 A phase I dose escalation study of BIBW-2992, an irreversible tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER-2) in a 2-week-on 2-weekoff schedule in patients with advanced solid tumors. Eskens FA, Mom C, Planting AS, Gietema A, Aamelsberg A, Verweij J, de Vries EG Clin Cancer Res 2005 11 23 Suppl Abs A 235
7. 790M EGFR mutants. Solca F, Schweifer N, Baum A, Rudolph D, Amelsberg A, Himmelsbach F, Beug H Clin Cancer Res 2005 11 23 Suppl Abs A 242
8. 636976 Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW-2992, an irreversible dual EGFR/HER-2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Stopfer P, Schaefer HG, Amelsberg A, Huisman H, Eskens F, Gietema JA, Briscoe J, Lewis N, Cohen RB, Marshall J, Verweij J CLIN CANCER RES 2005 11 23 Suppl Abs B172
9. 636988 A phase I dose escalation study of BIBW-2992, an irreversible dual EGFR/HER-2 receptor tyrosine kinase inhibitor, in a 3-week-on 1-week-off schedule in patients with advanced solid tumors. Marshall JL, Lewis NL, Amelsberg A, Briscoe J, Hwang J, Malik S, Cohen R CLIN CANCER RES 2005 11 23 Suppl Abs B
10. 670361 Phase 1 study with BIBW-2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER-2) in a 2-week-on 2-week-off schedule. Mom CH Proc Am Soc Clin Oncol 2006 25 Abs 3025
11. 670362 A phase I dose escalation study of BIBW-2992, an irreversible dual EGFR/HER-2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Shaw H Proc Am Soc Clin Oncol 2006 25 Abs 3027
12. 670942 A phase I dose escalation study of BIBW-2992, an irreversible dual EGFR/HER-2 receptor tyrosine kinase inhibitor, in a 3-week-on 1-week-off schedule in patients with advanced solid tumors. Lewis N Proc Am Soc Clin Oncol 2006 25 Abs 3091
13. 678221 NCT00225121: A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-00299804 in patients with advanced solid tumors. Pfizer Inc CLINICALTRIALS.GOV 2006 June 21
14. 742722 Phase I study of BIBW-2992, an oral irreversible dual EGFRsHER-2 inhibitor, showing activity in tumours with mutated EGFR. Plummer R, Vidal L, Li L, Shaw H, Perrett R, Shahidi M, Amelsberg A, Temple G, Calvert H, de Bono J EUR J CANCER 2006 4 12 Abs 573
15. 742739 Efficacy of BIBW-2992, an irreversible dual EGFRsHER-2 receptor tyrosine kinase inhibitor, in combination with cytotoxic agents. Solca F, Baum A, Himmelsbach F, Amelsberg A, Adolf G Eur J Cancer 2006 4 12 Abs 567
16. 761514 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER-3. Sergina NV, Rausch M, Wang DH, Blair J, Hann B, Shokat KM, Moasser MM Nature 2007 445 7126 437-441
17. 824532 NCT00514943: BIBW-2992 in head & neck cancer. Boehringer Ingelheim Pharmaceuticals clinicaltrials.gov 2007 August 15
18. 844712 A phase I dose finding study of a 3-day administration of BIBW-2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with 3-weekly docetaxel in patients with advanced solid tumors. Schoffski P, Dumez H, Wolter P, Hendlizs A, Besse-Hammer T, Piccart M, Selleslach J, Shahidi M, Taton M, Awada A AACR-NCI-EORTC Int Congress 2007 19 Abs B239
19. 855577 NCT00553254: A phase I/II trial to determine the recommended dose and evaluate the effectiveness of PF-00299804 in patients in Korea with advanced non-small-cell lung cancer not responding to platinum and erlotinib or gefitinib treatment. CLINICALTRIALS.GOV 2007 November 02.
20. 871307 A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER-2) tyrosine kinase in a 2-week-on, 2-week-off schedule in patients with advanced solid tumors. Eskens F, Mom CH, Planting AST, Gietema JA, Amelsberg A, Huisman H, van Doorn L, Burger H, Stopfer P, Verweij J, de Vries E Br J Cancer 2008 98 1 80-85
21. 877055 Boehringer Ingelheim's BIBW-2992 receives US Fast Track status for lung cancer. Boehringer Ingelheim Corp Press Release 2008 February 15
22. 894077 American Chemical Society 235th National Meeting (Part II) - Overnight Report, New Orleans, LA, USA. Lakeram M IDDB METING REPORT 2008 April 06-10
23. 894633 Boehringer Ingelheim annual press conference 2008. Boehringer Ingelheim Corp COMPANY PRESENTATION 2008 April 08
24. 894699 NCT00431067: Phase II trial of BIBW-2992 in patients with HER-2-positive metastatic breast cancer after failure of trastuzumab therapy. clinicaltrials.gov 2008 March 27
25. 894704 NCT00425854: An open label phase II trial of BIBW-2992 in patients with HER-2-negative metastatic breast cancer. clinicaltrials. gov 2008 March 31
26. 898009 Roche continues solid sales growth in first quarter of 2008 - both divisions significantly outpace their markets. Roche Holding AG PRESS RELEASE 17 April 2008
27. 910881 Use of BIBW-2992, a novel irreversible EGFR/HER-2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial. Yang C, Shih J, Chao T, Tsai C, Yu C, Yang P, Streit M, Shahidi M, Miller VA AM SOC CLIN ONCOL AN MET 2008 44 Abs 8026
28. 912521 American Society for Clinical Oncology - 44th Annual Meeting (Part IV) - Overnight Report, Chicago, IL, USA. Kibble A IDDB METING REPORT 2008 May 30-June 03
29. 915463 Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS Mayo Clin Proc 2008 83 6 679-686
30. 921775 Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Riely GJ J Thoracic Oncol 2008 3 6 Suppl 2 S146-S149
31. 921779 Combination of EGFR/HER-2 tyrosine kinase inhibition by BIBW 2992 and BIBW-2669 with irradiation in FaDu human squamous cell carcinoma. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca F, Baumann M, Krause M Strahlenther Onkol 2007 183 5 256-264
32. 921781 Efficacy of BIBW-2992, a potent irreversible inhibitor of EGFR and HER-2, in models of head and neck cancer. Solca F, Baum A, Krause M, Baumann M, Wong KK, Greulich H, Adolf G EJC SUPPL 2007 5 4 326-327
33. 921783 A phase I and pharmacokinetic (PK) study of BIBW-2992, an oral irreversible dual EGFR/HER-2 inhibitor. Plummer R, Vida L, Perrett R, Spicer J, Stopfer P, Shahidi M, Temple G, Futreal A, Calvert H, de Bono J EJC SUPPL 2007 5 4 Abs 703
34. 926513 Efficacy of BIBW-2992, a potent irreversible inhibitor of EGFR and HER-2 in human NSCLC xenografts and in a transgenic mouse lung-cancer model. Shimamura T, Greulich H, Solca FF, Wong KK J Thoracic Oncol 2007 2 8 Abs C7-04
35. 941562 Antitumor activity and pharmacokinetic properties of PF-00299804, a second generation irreversible pan-ErbB receptor tyrosine kinase inhibitor. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, Delaney AM, Harvey PJ, Ellis TA, Amato DM, Nelson JM, Fry DW et al MOL CANCER THER 2008 7 1880-1889
36. 941940 Expression of epidermal growth factor receptor (EGF-R) in human lung tumors. Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N Br J Cancer 1986 54 2 265-269
37. 941941 Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J Nature 1985 313 5998 144-147
38. 941943 EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R Anticancer Res 1997 17 1B 613-619
39. 941944 Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M J Urol 1993 150 1 126-131
40. 941945 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R et al J Clin Oncol 2003 21 12 2237-2246
41. 941946 Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC Clin Cancer Res 1999 5 12 4164-4174
42. 941950 Prognostic influence of the coexpression of epidermal growth factor receptor and c-ErbB-2 protein in human lung adenocarcinoma. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K Surg Oncol 1994 3 2 109-113
43. 941960 Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Sordella R, Bell DW, Haber DA, Settleman J Science 2004 305 5678 1163-1167
44. 941965 HER-2 kinase domain mutation results in constitutive phosphorylation and activation of HER-2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL Cancer Cells 2006 10 1 25-38
45. 941968 BIBW-2992, an irreversible EGFR/HER-2 inhibitor highly effective in preclinical lung cancer models. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ et al Oncogene 2008 27 34 4702-4711
46. 14C-BIBW-2992 oral solution in healthy male volunteers. Stopfer P AM SOC CLIN ONCOL AN MET 2008 Abs 14607
47. 942181 A phase II trial of weekly alternating sequential administration of BIBF-1120 and BIBW-2992 in patients with advanced colorectal cancer. Bouche O, Ducreux M, Lledo G, Andre T, Maindrault-Goebel F, Stopfer P, Oum'Hamed Z, Chadjaa M, de Gramont A AM SOC CLIN ONCOL AN MET 2008 26 Abs 15001
48. 942183 NCT00706628: A multi-centre 3-arm randomized phase II trial of BIBF-1120 versus BIBW-2992 versus sequential administration of BIBF-1120 and BIBW-2992 in patients with hormone-resistant prostate cancer. clinicaltrials.gov 2008 June 24
49. 942184 NCT00727506: BIBW-2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma. clinical trials.gov 2008 July 31
50. 942186 NCT00711594: Phase I/II open label trial of continuous once daily oral treatment with BIBW-2992 - Phase I trial in advanced non-small-cell lung cancer patients and phase II trial in non-small-cell lung cancer patients failing erlotinib or gefitinib. clinicaltrials.gov 2008 October 23
51. 942187 NCT00656136: BIBW-2992 (TOVOK) and BSC versus placebo and BSC in non-small-cell lung cancer patients failing erlotinib or gefitinib. clinicaltrials.gov 2008 April
52. 942188 Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG et al J Clin Oncology 2005 23 31 7775-7776
53. 942189 A phase III randomized, open-label international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Geyer CE, Cameron DW, Lindquist S AM SOC CLIN ONCOL AN MET 2006 42
54. 942209 Medicinal chemistry - XXth International symposium (Part III), lead finding strategies and kinase selectivity, Vienna, Austria. Rotella DP IDDB METING REPORT 2008 August 31-September 04
55. 948149 WO-2007085638: Process for preparing aminocrotonylamino- substituted quinazoline derivatives. Schroeder J, Dziewas G, Fachinger T, Jaeger B, Reichel C, Renner S World Patent 2007 August 02
56. 949320 Protein tyrosine kinase structure and function. Hubbard SR, Till JH Annu Rev Biochem 2000 69 373-398
57. 949321 Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Nemunaitis J, Eiseman I, Cunningham C, Senzer N, Williams A, Lenehan PF, Olson SC, Bycott P, Schlicht M, Zentgraff R, Shin DM et al Clin Cancer Res 2005 11 10 3846-3853
58. 949322 Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. Campos S, Hamid O, Seiden MV, Oza A, Plante M, Potkul RK, Lenehan PF, Kaldjian EP, Varterasian ML, Jordan C, Charbonneau C et al J Clin Oncol 2005 23 24 5597-5604
59. 950374 Adjuvant trastuzumab therapy for HER-2-positive breast cancer. Jahanzeb M CLIN BREAST CANCER 2008 8 4 324-333
60. 950377 First-line Herceptin monotherapy in metastatic breast cancer. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ ONCOLOGY 2001 61 Suppl 2 37-42.